Supernus Pharmaceuticals Inc (SUPN)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	141	25,622	43,347	52,043	60,711	37,672	57,485	73,346	53,424	81,750	100,185	111,126	126,950	129,311	118,174	116,234	113,056	105,820	104,971	102,981
Total stockholders’ equity	US$ in thousands	1	912,191	919,908	912,150	0	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383	595,428	557,257	522,904	480,018
ROE		14,100.00%	2.81%	4.71%	5.71%	—	4.42%	6.83%	8.85%	6.55%	10.09%	12.75%	14.73%	17.04%	18.24%	17.74%	18.95%	18.99%	18.99%	20.07%	21.45%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $141K ÷ $1K
= 14,100.00%

Supernus Pharmaceuticals Inc's return on equity (ROE) has shown a declining trend over the past eight quarters. In Q4 2023, the ROE was 0.14%, significantly lower than the previous quarter, where it stood at 2.81%. This decline indicates that the company's profitability in relation to shareholders' equity has decreased.

Looking at a longer time frame, Supernus Pharmaceuticals Inc's ROE has been gradually decreasing from 8.85% in Q1 2022 to the current level of 0.14% in Q4 2023. This downward trend may raise concerns about the company's ability to generate profits from shareholders' equity effectively.

Overall, the decreasing trend in Supernus Pharmaceuticals Inc's ROE suggests that the company may be facing challenges in maximizing shareholder value through its operations and investments. It would be important for the company to analyze the factors impacting its ROE and take appropriate measures to improve this key financial metric.